What is the difference between Fiasp and NovoLog?

Fiasp (insulin aspart) is a newer formulation of NovoLog with niacinamide (vitamin B3) added. Niacinamide helps to increase the speed of the initial absorption of insulin, resulting in an onset of appearance in the blood approximately 2.5 minutes after administration.

Fiasp is a fast-acting mealtime insulin for use in adults with type 1 diabetes and type 2 diabetes, and children with type 1 diabetes.

Fiasp subcutaneous injection can be used at the beginning of a meal or within 20 minutes after starting a meal.

Fiasp is available as an Injection 100 units/mL (U-100):

• 10 mL multiple-dose vial
• 3 mL single-patient-use FIASP FlexTouch® pen
• 3 mL single-patient-use PenFill® cartridges for use in a PenFill cartridge device

NovoLog also is indicated for use in adults with type 1 and type 2 diabetes, and children with type 1 diabetes.

NovoLog subcutaneous injection is administered 5-10 minutes before a meal.

NovoLog is available as an Injection 100 units/mL (U-100):

• 10 mL multiple-dose vial
• 3 mL single-patient-use PenFill® cartridges for the 3 mL PenFill cartridge device
• 3 mL single-patient-use NovoLog FlexPen®
• 3 mL single-patient-use NovoLog FlexTouch®

Both Fiasp and NovoLog can be administered as a subcutaneous injection, continuous subcutaneous infusion via insulin pump, or as an intravenous infusion under medical supervision.